Background The antiplatelet activity of clopidogrel is variable among patients suffering from
ischemic heart disease. Variation in the cytochrome P450 2C19 (CYP2C19) gene coding for …

Genetic variation in the cytochrome P450 2C19 (CYP2C19) gene has been documented
gradually as the determinant conversion and variability in the antiplatelet effect of …

Clopidogrel, an antiplatelet drug, is frequently prescribed to patients diagnosed with
ischemic diseases such as those suffering from acute coronary syndromes or ischemic …

Background Cytochrome P450 family 2 subfamily C member 19 (CYP2C19) is a hepatic
enzyme involved in the metabolism of clopidogrel from a prodrug to its active metabolite …

What is known and objective Variation of the cytochrome P450 2C19 gene coding for the
CYP 2C19 enzyme has been reported to be associated with clopidogrel response variability …

Abstract Background Cytochrome P450 2C19 (CYP2C19) loss-of-function polymorphisms
are more common in Asian populations and have been associated with diminished …

Purpose Some studies in the white population have shown that carriers of at least 1 loss-of-
function allele in the gene that encodes the cytochrome P-450 2C19 isozyme (CYP2C19) …

The extent to which cytochrome P450 (CYP) 2C19 genotype influences the effectiveness of
clopidogrel remains uncertain due to considerable heterogeneity between studies. We used …

Whether the current pharmacogenetic knowledge of clopidogrel could be translated into
Chinese clinical practice is yet to be defined. To address this issue, we assessed the relation …

Aims/objective Influence of genetic variations on the response of clopidogrel, an antiplatelet
drug is implicated. In the present study, the prevalence of single nucleotide polymorphisms …